Latest Headlines in Biotech
Boston biotech’s drug for rare liver disease will cost $385,000 a year
The day after winning its first US drug approval, Albireo Pharma disclosed an eye-popping list price for its new medicine.
How an unproven Alzheimer’s drug got approved
Two months before the Food and Drug Administration’s deadline to decide whether to approve Biogen’s controversial Alzheimer’s drug aducanumab, a council of senior agency officials resoundingly agreed that there wasn’t enough evidence it worked.
How an unproven Alzheimer’s drug got approved
Two months before the FDA's deadline to decide whether to approve Biogen’s controversial Alzheimer’s drug aducanumab, a council of senior agency officials resoundingly agreed that there wasn’t enough evidence it worked.
Cambridge biotech raises $135 million for experimental ALS drug
Amylyx Pharmaceuticals plans to use the money to continue work on its experimental medicine for amyotrophic lateral sclerosis, or Lou Gehrig’s disease.
Weight-loss firm Gelesis to go public in $1.3 billion SPAC merger
Gelesis said it would use the money to fund the full commercial launch of its weight-loss treatment — which can be prescribed to adults with a BMI between 25 and 40 — later this year.
Waltham cancer-drug startup TScan sees stock fall in public market debut
TScan is working on programs for both solid and liquid tumors, and it expects to submit two investigational new drug applications for its lead programs, which aim to prevent relapses in blood cancers, by the end of the year.
Startup Prime Medicine emerges with $315m to pioneer a new type of gene editing
The Cambridge company was founded by David Liu, a Broad Institute of MIT and Harvard researcher.
FDA head calls for federal probe into approval of Biogen’s Alzheimer’s drug
It’s the latest fallout over last month’s approval of Aduhelm, an expensive and unproven therapy from Cambridge drugmaker Biogen that the agency OK’d in June against the advice of its own outside experts.